Clinical Trials Directory

Trials / Completed

CompletedNCT03766672

Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
University Hospital Center of Martinique · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

In Martinique, about 33 new cases are diagnosed per year, with a high incidence rate of type 2 endometrial carcinoma which has a poor prognosis with few therapeutic options. Although targeted therapies are used in many types of cancer, they are still possible a minority of patients. In current practice, endometrial cancers do not benefit these therapies. Characterization of the molecular mechanisms involved in the genesis of type 2 endometrial carcinoma could help to identify biomarkers predictive of a response to targeted therapies. We propose to identify the genetic profile of type 2 endometrial carcinomas in Martinique.

Detailed description

Type 2 endometrial carcinomas are often diagnosed at advanced stages, with an high risk of metastatic recurrence and death even when diagnosed at early stages. They also have few therapeutic options. The Characterize the mutations responsible of cancer development has led to develope "precision medicine" that targets "actionable genes" by a drug. This concept of actionable mutation refers to a change in the DNA molecule that can predict the response to a drug defined as targeted therapy. Although targeted therapies are used in many types of cancer, they still target a minority of patients. Some tumor sites still do not benefit from these treatments. Specifically, type 2 endometrial cancers that have poor prognosis with few therapeutic options. The characterization of molecular mechanisms, by Next Generation Sequencing (NGS), involved in the carcinogenesis of endometrial cancers, particularly type 2 cancers, should allow the identification of predictive biomarkers for response to certain targeted therapies.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTIntervention ArmThe intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.

Timeline

Start date
2019-11-22
Primary completion
2021-11-22
Completion
2024-07-22
First posted
2018-12-06
Last updated
2024-08-21

Locations

1 site across 1 country: Martinique

Source: ClinicalTrials.gov record NCT03766672. Inclusion in this directory is not an endorsement.